McMaster Hemophilia Research Group

Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.
Iorio A, Fischer K, Makris M. Br J Haematol. 2017 Jul;178(1):20-31.
doi: 10.1111/bjh.14610. Review. PMID: 28387451

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Thromb Haemost. 2017 Jun 2;117(6):1023-1030. doi: 10.1160/TH16-12-0942. PMID: 28357444

Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation.
Lawson W, Uy M, Strike K, Iorio A, Stein N, Koziol L, Chan A. Haemophilia. 2017 Jun 2.
doi: 10.1111/hae.13269. PMID: 28574191

Switching to extended half-life products in Canada - preliminary data.
Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S; Association of Hemophilia Centre Directors of Canada (AHCDC). Haemophilia. 2017 May 26.
doi: 10.1111/hae.13245. PMID: 28548284

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Haemophilia. 2017 May;23(3):e170-e179.
doi: 10.1111/hae.13215. PMID: 28345268

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P. Haemophilia. 2017 May;23(3):408-416.
doi: 10.1111/hae.13160. PMID: 28233383

Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development.
Iorio A. Haemophilia. 2017 May;23(3):350-352.
doi: 10.1111/hae.13176. PMID: 28220559

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P. J Med Econ. 2017 Apr;20(4):337-344.
doi: 10.1080/13696998.2016.1265973. PMID: 27885871

Thrombosis in Inherited Fibrinogen Disorders.
Korte W, Poon MC, Iorio A, Makris M. Transfus Med Hemother. 2017 Apr;44(2):70-76.
doi: 10.1159/000452864. Review. PMID: 28503122

Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics - impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment.
Iorio A, Edginton AN. Haemophilia. 2017 Mar 21.
doi: 10.1111/hae.13210. PMID: 28326647

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T, Mauser-Bunschoten E, Mingot-Castellano ME, Ozdemir N, Pabinger I, Parra R, Pasi J, Peerlinck K, Rauch A, Roussel-Robert V, Serban M, Tagliaferri A, Windyga J, Zanon E. Haemophilia. 2017 Mar;23(2):255-263.
doi: 10.1111/hae.13167. PMID: 28205285

The current state of adverse event reporting in hemophilia.
van Vulpen LF, Saccullo G, Iorio A, Makris M. Expert Rev Hematol. 2017 Feb;10(2):161-168.
doi: 10.1080/17474086.2017.1272410. Review. PMID: 28013565

Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data.
Iorio A, Stonebraker JS, Brooker M, Soucie JM; Data and Demographics Committee of the World Federation of Hemophilia. Haemophilia. 2017 Jan;23(1):e1-e7.
doi: 10.1111/hae.13127. PMID: 27928881

The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study.
Sun J, Zhao Y, Yang R, Guan T, Iorio A; Chinese HERO study group. Haemophilia. 2017 Jan;23(1):89-97.
doi: 10.1111/hae.13071. PMID: 27599642

Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.
Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network. JMIR Res Protoc. 2016 Dec 15;5(4):e239. PMID: 27977390

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).
McEneny-King A, Foster G, Iorio A, Edginton AN. JMIR Res Protoc. 2016 Dec 7;5(4):e232. PMID: 27927609

Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.
Cheng J, Iorio A, Marcucci M, Romanov V, Pullenayegum EM, Marshall JK, Thabane L. J Blood Med. 2016 Oct 25;7:239-253. eCollection 2016. PMID: 27822129

The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.
McEneny-King A, Iorio A, Foster G, Edginton AN. Expert Opin Drug Metab Toxicol. 2016 Aug 19:1-9. PMID: 27539370

Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH.
Iorio A, Barbara AM, Bernardi F, Lillicrap D, Makris M, Peyvandi F, Rosendaal F; Subcommittee on Factor VIII, Factor IX & Rare Coagulation Disorder. J Thromb Haemost. 2016 Aug;14(8):1668-72.
doi: 10.1111/jth.13382. PMID: 27496160

Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases.
Yeung CH, Santesso N, Zeraatkar D, Wang A, Pai M, Sholzberg M, Schünemann HJ, Iorio A. Haemophilia. 2016 Jul;22 Suppl 3:41-50.
doi: 10.1111/hae.13010. PMID: 27348400

Care models in the management of haemophilia: a systematic review.
Yeung CH, Santesso N, Pai M, Kessler C, Key NS, Makris M, Navarro-Ruan T, Soucie JM, Schünemann HJ, Iorio A. Haemophilia. 2016 Jul;22 Suppl 3:31-40.
doi: 10.1111/hae.13000. Review. PMID: 27348399

Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study.
Lane SJ, Sholapur NS, Yeung CH, Iorio A, Heddle NM, Sholzberg M, Pai M. Haemophilia. 2016 Jul;22 Suppl 3:23-30.
doi: 10.1111/hae.13009. PMID: 27348398

Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management.
Pai M, Santesso N, Yeung CH, Lane SJ, Schünemann HJ, Iorio A. Haemophilia. 2016 Jul;22 Suppl 3:17-22.
doi: 10.1111/hae.13007. PMID: 27348397

NHF-McMaster Guideline on Care Models for Haemophilia Management.
Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris M, Riker E, Santesso N, Soucie JM, Yeung CH, Iorio A, Schünemann HJ. Haemophilia. 2016 Jul;22 Suppl 3:6-16.
doi: 10.1111/hae.13008. Review. PMID: 27348396

Report on the International Society for Laboratory Hematology Survey on guidelines to support clinical hematology laboratory practice.
Hayward CP, Moffat KA, George TI, Proytcheva M, Iorio A. Int J Lab Hematol. 2016 May;38 Suppl 1:133-8.
doi: 10.1111/ijlh.12501. PMID: 27160952

Haemophilia in a real-world setting: the value of clinical experience in data collection.
Dolan G, Iorio A, Jokela V, Juusola K, Lassila R. Eur J Haematol. 2016 Feb;96 Suppl 82:3-9.
doi: 10.1111/ejh.12715. PMID: 26809546

FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies.
Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators. Haemophilia. 2016 Jan;22(1):e36-8.
doi: 10.1111/hae.12764. PMID: 26208036

Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Cochrane Database Syst Rev. 2015 Dec 16;(12):CD004449.
doi: 10.1002/14651858.CD004449.pub4. Review. PMID: 26677005

Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study.
Palareti L, Potì S, Cassis F, Emiliani F, Matino D, Iorio A. Int J Qual Stud Health Well-being. 2015 Nov 16;10:28915.
doi: 10.3402/qhw.v10.28915. eCollection 2015. PMID: 26578360

Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant Factor Viii Fc Fusion Protein and conventional recombinant Factor Viii.
Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Value Health. 2015 Nov;18(7):A660.
doi: 10.1016/j.jval.2015.09.2393. PMID: 26533703

Factor consumption for prophylaxis and treatment of bleeding: recombinant Factor Ix Fc Fusion Protein compared with conventional recombinant Factor Ix.
Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Value Health. 2015 Nov;18(7):A660.
doi: 10.1016/j.jval.2015.09.2396. PMID: 26533702

Modeling the impact of potential differences in real-world adherence with extended-half-life vs conventional Factor Viii and Ix on bleeding.
Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Value Health. 2015 Nov;18(7):A660-1.
doi: 10.1016/j.jval.2015.09.2397. PMID: 26533698

Individualizing factor replacement therapy in severe hemophilia.
Carcao MD, Iorio A. Semin Thromb Hemost. 2015 Nov;41(8):864-71.
doi: 10.1055/s-0035-1552563. Review. PMID: 26270111

Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study).
Minuk L, Jackson S, Iorio A, Poon MC, Dilworth E, Brose K, Card R, Rizwan I, Chin-Yee B, Louzada M. Haemophilia. 2015 Nov;21(6):736-41.
doi: 10.1111/hae.12768. PMID: 26222883

Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation.
Strike KL, Iorio A, Jackson S, Lawson W, Scott L, Squire S, Chan AK. Haemophilia. 2015 Nov;21(6):828-31.
doi: 10.1111/hae.12767. PMID: 26208178

A systematic review of definitions and reporting of bleeding outcome measures in haemophilia.
Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A. Haemophilia. 2015 Nov;21(6):731-5.
doi: 10.1111/hae.12750. Review. PMID: 26179330

IDO1 suppresses inhibitor development in hemophilia A treated with Factor VIII.
Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F. J Clin Invest. 2015 Oct 1;125(10):3766-81.
doi: 10.1172/JCI81859. PMID: 26426076

Inhibitor development in non-severe haemophilia across Europe. Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants. Thromb Haemost. 2015 Oct;114(4):670-5.
doi: 10.1160/TH14-12-1044. PMID: 26293381

Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
Romanov V, Marcucci M, Cheng J, Thabane L, Iorio A. Thromb Haemost. 2015 Jun 30;114(1):56-64.
doi: 10.1160/TH14-10-0882. PubMed PMID: 26017627

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.
Berntorp E, Iorio A. Blood. 2015 Jun 11;125(24):3816-7.
doi: 10.1182/blood-2014-10-608471. PubMed Central PMCID: PMC4471774. PubMed PMID:26069334

Cardiovascular disease prevalence and relevance in haemophilia: a scoping review.
Rizwan I, Minuk L, Jackson S, Iorio A. Haemophilia. 2015 May;21(3):e156-66. doi: 10.1111/hae.12596. PMID: 25420604.

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Thromb Haemost. 2015 May;113(5):958-67. doi:10.1160/TH14-07-0621. PMID: 25631402.

Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; EUHASS participants. Thromb Haemost. 2015 May;113(5):968-75. doi: 10.1160/TH14-10-0826. PMID: 25567324

Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Haemophilia. 2015 Mar;21(2):204-9. doi: 10.1111/hae.12550. PMID: 25274155. PMID: 25377442

Treatment decision-making among Canadian youth with severe haemophilia: a qualitative approach.
Lane SJ, Walker I, Chan AK, Heddle NM, Poon MC, Minuk L, Jardine L, Arnold E, Sholapur N, Webert KE. Haemophilia. 2015 Mar;21(2):180-9. doi:10.1111/hae.12543. PMID: 2529666 PMID: 25273544

Pharmacokinetics of plasma derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Haemophilia. 2015 Mar;21(2):204-9. doi: 10.1111/hae.12550. PMID: 25274155

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions.
Jackson SC, Yang M, Minuk L, Sholzberg M, St-Louis J, Iorio A, Card R, Poon MC. BMC Hematol. 2015 Feb 14;15:4. doi: 10.1186/s12878-015-0022-8. eCollection 2015. PubMed Central PMCID: PMC4331146. PubMed PMID: 25692030

Haemophilia Experiences, Results and Opportunities (HERO) study: treatmentrelated characteristics of the population.
Nugent D, Kalnins W, Querol F, Gregory M, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2015 Jan;21(1):e26-38. doi: 10.1111/hae.12545. PMID: 25377442

Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors.
McCarthy A, Moore A, Redhead L, McLaughlin P, Iorio A, Chowdary P. Haemophilia. 2015 Jan;21(1):116-23. doi:10.1111/hae.12500. PMID: 25421726. PMID: 25273544

Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population.
Nugent D, Kalnins W, Querol F, Gregory M, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2015 Jan;21(1):e26-38. doi: 10.1111/hae.12545. PMID: 25377442. PMID: 25273544

Patient data metaanalysis of PostAuthorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHFPFM.
Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L. Haemophilia. 2014 Nov;20(6):77783. doi: 10.1111/hae.12480. PMID: 25039809

Developing a two sided intervention to facilitate shared decisionmaking in haemophilia: decision boxes for clinicians and patient decision aids for patients.
Athale A, Giguere A, Barbara A, Krassova S, Iorio A. Haemophilia. 2014 Nov;20(6):8006.doi: 10.1111/hae.12495. Epub 2014 Oct 2. PMID: 25273544

Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward.
Matino D, Iorio A. Haemophilia. 2014 Sep;20(5):6046. doi: 10.1111/hae.12511. Epub 2014 Aug 25. PMID: 25154445

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.
Traore AN, Chan AK, Webert KE, Heddle N, Ritchie B, StLouis J, Teitel J, Lillicrap D, Iorio A, Walker I. Haemophilia. 2014 Jul;20(4):e2519. doi: 10.1111/hae.12477. PMID: 24948405

Aryl hydrocarbon receptor control of a disease tolerance defence pathway.
Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Bicciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P. Nature. 2014 Jul 10;511(7508):18490. doi: 10.1038/nature13323. PMID: 24930766

Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia.
Cassis FR, Buzzi A, Forsyth A, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2014 Jul;20(4):e28795. doi: 10.1111/hae.12454. Epub 2014 May 7. PMID: 24800872

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.
Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Haemophilia. 2014 Jul;20(4):52734. doi: 10.1111/hae.12371. Epub 2014 Jan 29. PMID: 24471912

First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.
Traore AN, Chan AK, Webert KE, Heddle N, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A, Walker I. Haemophilia. 2014 Jul;20(4):e251-9. doi: 10.1111/hae.12477. PMID: 24948405

Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Int J Lab Hematol. 2014 Jun;36(3):34151.doi: 10.1111/ijlh.12218. PMID: 24750681

Joint WFHISTH session: issues in clinical trial design.
Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Haemophilia. 2014 May;20 Suppl 4:13744.doi: 10.1111/hae.12415. PMID: 24762289

Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B.
Jackson SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC. Haemophilia. 2014 May;20(3):e199204. doi: 10.1111/hae.12391. Epub 2014 Mar 3. PMID: 24589126

Joint WFH-ISTH session: issues in clinical trial design.
Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Haemophilia. 2014 May;20 Suppl 4:137-44. doi: 10.1111/hae.12415. PubMed PMID: 24762289.

Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia.
Cassis FR, Buzzi A, Forsyth A, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2014 May 7. doi: 10.1111/hae.12454. [Epub ahead of print] PubMed PMID: 24800872.

The haemophilia certification system in Canada.
Matino D, Teitel J, Page D, Keepanasseril A, Iorio A, Walker I. Blood Transfus. 2014 Apr;12 Suppl 3:e53141. doi: 10.2450/2014.003214s. PMID: 24922284

Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.
Athale AH, Marcucci M, Iorio A. Cochrane Database Syst Rev. 2014 Apr 24;4:CD010561. doi: 10.1002/14651858.CD010561.pub2. PMID: 24763974

Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B.
Athale AH, Marcucci M, Iorio A. Cochrane Database Syst Rev. 2014 Apr 24;4:CD010561. doi: 10.1002/14651858.CD010561.pub2. PubMed PMID: 24763974 .

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, SaintRemy JM, Schramm W, Iorio A. Haemophilia. 2014 Mar;20(2):2006. doi: 10.1111/hae.12283. Epub 2013 Oct 29. PMID: 24533949

What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia.
Arnold E, Lane S, Webert KE, Chan A, Walker I, Tufts J, Rubin S, Poon MC, Heddle NM. Haemophilia. 2014 Mar;20(2):219-25. doi: 10.1111/hae.12297. Epub 2013 Nov 20. PMID: 24252098

The Hemophilia Certification System in Canada.
Matino D, Teitel J, Page D, Keepanasseril A, Iorio A, Walker I. Blood Transfus. 2014 Apr;12 Suppl 3:e531-41. doi: 10.2450/2014.0032-14s. PubMed PMID: 24922284.

Treatment decision-making among Canadian youth with severe hemophilia: a qualitative approach.
Lane SJ, Walker I, Chan AK, Heddle NM, Poon, MC, Minuk L, Jardine L, Arnold E, Sholapur N, Webert KE. Haemophilia. 2015 Mar;21(2):180-9. doi: 10.1111/hae.12543. Epub 2014 Oct 9. PMID: 25296666.

Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics.
Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2014 Jan;20(1):4451. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PMID: 23902228

What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers.
Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM. Haemophilia. 2013 Jul;19(4):503-10. doi: 10.1111/hae.12104. Epub 2013 Apr 1. PMID: 23551887

Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin.
Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Int J Lab Hematol. 2014 Jun;36(3):341-51. doi: 10.1111/ijlh.12218. PubMed PMID: 24750681

Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B.
Jackson SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC.
Haemophilia. 2014 May;20(3):e199-204. doi: 10.1111/hae.12391. Epub 2014 Mar 3. PubMed PMID: 24589126

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Haemophilia. 2014 Mar;20(2):200-6. doi: 10.1111/hae.12283. Epub 2013 Oct 29. PubMed PMID: 24533949.

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.
Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Haemophilia. 2014 Jan 29. doi: 10.1111/hae.12371. [Epub ahead of print] PubMed PMID: 24471912.

Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics.
Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2014 Jan;20(1):44-51. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PubMed PMID: 23902228.

What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providers.
Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM. Haemophilia 2013;19:503–10. PubMed PMID: 23551887

Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity.
Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Haemophilia. 2014 Mar;20(2):200-6. doi: 10.1111/hae.12283. Epub 2013 Oct 29. PubMed PMID: 24533949.

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.
Halimeh S, Bidlingmaier C, Heller C, Gutsche S, Holzhauer S, Kenet G, Kurnik K, Manner D, Iorio A, Nowak-Göttl U.  Biomed Res Int. 2013:901975. doi: 10.1155/2013/901975. Epub 2013 Oct 2. PubMed PMID: 24199202; PubMed Central PMCID: PMC3807559.

A survey of patients with haemophilia to understand how they track product used at home.
Sholapur NS, Barty R, Wang G, Almonte T, Heddle NM.  Haemophilia. 2013 Sep;19(5):e289-95. doi: 10.1111/hae.12170. Epub 2013 May 15. PubMed PMID: 23672744.

Evidence-based focused review of platelet transfusions for critically ill patients withthrombocytopenia.
Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth S, Arnold DM. Blood. 2013;123(8):1146-51

High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoingimmunotolerance.
Tagariello G, Iorio A, Matino D, Belvini D, Salviato R, Sartori R, Radossi P. J Hematol Oncol. 2013 Aug 30;6:63. doi: 10.1186/1756-8722-6-63. PubMed PMID: 24001010; PubMed Central PMCID: PMC3766100.

Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics.
Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia. 2014 Jan;20(1):44-51. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PubMed PMID: 23902228.

Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelettransfusions.
Estcourt LJ, Heddle NM, Kaufman R, McCullough J, Murphy MF, Slichter S, Wood EM, Stanworth SJ. Transfusion. 2013 Jul; 53(7):1531-43. PubMed PMID: 23305609.

Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.
Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A.J Thromb Haemost. 2013 Sep;11(9):1655-62. doi: 10.1111/jth.12335. Review. PubMed PMID: 23802542.

The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.
Kessler CM, Iorio A. Haemophilia. 2013 May;19(3):351-4. doi: 10.1111/hae.12149. Epub 2013 Apr 12. PubMed PMID: 23577743.

Factor VIII products and inhibitors in severe hemophilia A.
Iorio A, Skinner MW, Makris M. N Engl J Med. 2013 Apr 11;368(15):1456. doi: 10.1056/NEJMc1301995#SA1. PubMed PMID: 23574132.

Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project.
Santagostino E, Messina M, Tagliaferri A, Iorio A, Morfini M. Blood Transfus. 2013 Apr;11(2):272-80. doi: 10.2450/2012.0158-12. Epub 2013 Jan 23. PubMed PMID: 23399360; PubMed Central PMCID: PMC3626480.

A study of variations in the reported haemophilia B prevalence around the world.
Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. Haemophilia. 2012 May;18(3):e91-4. doi: 10.1111/j.1365-2516.2011.02588.x. Epub 2011 Jun 7. PMID:21649801

Low prevalence of inhibitor antibodies in the Canadian haemophilia population.
Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, St-Louis J, Walker IR. Haemophilia. 2012 May;18(3):e254-9. doi: 10.1111/j.1365-2516.2011.02694.x. Epub 2011 Nov 14. PMID: 22077390

The importance of haemophilia treatment centre administrators in patient care.
Almonte T, Decker K, Seroski W, Walker I, Webert K, Bos C, Strike K, Waterhouse L, Goldsmith R, Chan AK. Haemophilia. 2012 Sep;18(5):e366-7. doi: 10.1111/j.1365-2516.2012.02900.x. Epub 2012 Jul 15. PMID: 22805734

Genetics of haemostasis.
Goodeve AC, Perry DJ, Cumming T, Hill M, Jennings I, Kitchen S, Walker I, Gray E, Jayandharan GR, Tuddenham E. Haemophilia. 2012 Jul;18 Suppl 4:73-80. doi: 10.1111/j.1365-2516.2012.02832.x. Review. PMID: 22726087

Central nervous system bleeding in patients with rare bleeding disorders.
Siboni SM, Zanon E, Sottilotta G, Consonni D, Castaman G, Mikovic D, Biondo F, Tagliaferri A, Iorio A, Mannucci PM, Peyvandi F. Haemophilia. 2012 Jan;18(1):34-8. doi: 10.1111/j.1365-2516.2011.02545.x. Epub 2011 May 4. PMID: 21539694

Psychosocial aspects of haemophilia: a systematic review of methodologies and findings.
Cassis FR, Querol F, Forsyth A, Iorio A; HERO International Advisory Board. Haemophilia. 2012 May;18(3):e101-14. doi: 10.1111/j.1365-2516.2011.02683.x. Epub 2011 Nov 8. Review. PMID: 22059839

Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors.
Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, Coppola A, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers, Barillari G, Dragani A, Gamba G, Giuffrida A, Lapecorella M, Mancuso G, Lucia L, Mazzucconi MG, Messina M, Musso R, De Martis F, Rossetti G, Schinco P, Spiezia L, Valdrè L.Haemophilia. 2012 Jan;18(1):39-45. doi: 10.1111/j.1365-2516.2011.02611.x. Epub 2011 Jul 14.PMID: 21752159

Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle NM. Cochrane Database Syst Rev 2012 May 16; 5:CD004269. PubMed PMID: 22592695

A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia.
Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM. Transfusion 2012 Nov; 52(11):2466-74. PubMed PMID: 2248627

Psychosocial aspects of haemophilia: a systematic review of methodologies and findings.
Cassis FR, Querol F, Forsyth A, Iorio A; HERO International Advisory Board. Haemophilia. 2012 May;18(3):e101-14. doi: 10.1111/j.1365-2516.2011.02683.x. Epub 2011 Nov 8. Review. PubMed PMID: 22059839.

Clotting factor concentrate switching and inhibitor development in hemophilia A.
Iorio A, Puccetti P, Makris M. Blood. 2012 Jul 26;120(4):720-7. doi:10.1182/blood-2012-03-378927. Epub 2012 Jun 12. PubMed PMID: 22692511.

Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors.
Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, Coppola A, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers, Barillari G, Dragani A, Gamba G, Giuffrida A, Lapecorella M, Mancuso G, Lucia L, Mazzucconi MG, Messina M, Musso R, De Martis F, Rossetti G, Schinco P, Spiezia L, Valdrè L. Haemophilia. 2012 Jan;18(1):39-45. doi: 10.1111/j.1365-2516.2011.02611.x. Epub 2011 Jul 14. PubMed PMID: 21752159.

Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K, Walker I, Decker K, Chan AK, Pai MK. Haemophilia. 2011 Nov;17(6):872-4. doi: 10.1111/j.1365-2516.2011.02506.x. Epub 2011 Feb 22. PMID: 21342368

Clotting factorconcentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD003429. doi: 10.1002/14651858.CD003429. pub4. Review. PubMed PMID: 21901684.

Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Federici AB, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci PM. Semin Thromb Hemost. 2011 Jul;37(5):511-21. doi: 10.1055/s-0031-1281037. Epub 2011 Nov 18. PubMed PMID: 22102194.

Concentrate-related inhibitor risk: is a difference always real?
Iorio A, Marcucci M, Makris M. J Thromb Haemost. 2011 Nov;9(11):2176-9. doi: 10.1111/j.1538-7836.2011.04480.x. PubMed PMID: 21854537.

Time to rethink clinically important outcomes in platelet transfusion trials.
Heddle NM, Arnold DM, Webert KE. Transfusion 2011 Feb; 51(2):430-4. PubMed PMID: 21309780

Adjudicating bleeding events in a platelet dose study: Impact on outcome results and challenges.
Heddle NM, Wu C, Vassallo R, Carey P, Arnold DM, Lozano M, Pavenski K, Sweeney J, Stanworth S, Liu Y, Traore AN, Barty RL, Tinmouth A. Transfusion. 2011 Nov;51(11):2304-10. PubMed PMID: 21599672

Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.
Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. Italian ad hoc study group. Blood Transfus. 2011 Jan;9(1):60-9. doi: 10.2450/2010.0011-10. Epub 2010 Apr 30. PubMed PMID: 21084016; PubMed Central PMCID: PMC3021399.

A study of variations in the reported haemophilia A prevalence around the world.
Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. Haemophilia. 2010 Jan;16(1):20-32. doi: 10.1111/j.1365-2516.2009.02127.x. Epub 2009 Oct 21. PMID: 19845775

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. Review. PubMed PMID: 20345722.

Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A, Matino D, D'Amico R, Makris M. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004449. doi: 10.1002/14651858.CD004449.pub3. Review. PubMed PMID: 20687076.

Mortality and causes of death in Italian persons withhaemophilia, 1990-2007.
Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M; Italian Association of Hemophilia Centers, Ciavarella N, Scaraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenzi D, Serino ML, Linari S, Molinari C, Boeri E, La Pecorella M, Carloni MT, Santagostino E, Di Minno G, Coppola A, Rocino A, Zanon E, Spiezia L, Di Perna C, Marchesini M, Marcucci M, Dragani A, Macchi S, Albertini P, D'Incà M, Santoro C, Biondo F, Piseddu G, Rossetti G, Barillari G, Gandini G, Giuffrida AC, Castaman G. Haemophilia. 2010 May;16(3):437-46. doi: 10.1111/j.1365-2516.2009.02188.x. Epub 2010 Feb 9. PubMed PMID: 20148978.

Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care.
Teitel JM, Carcao M, Lillicrap D, Mulder K, Rivard GE, St-Louis J, Smith F, Walker I, Zourikian N. Haemophilia. 2009 Jan;15(1):227-39. doi: 10.1111/j.1365-2516.2008.01840.x. Epub 2008 Aug 25. Review. PMID: 18752535

Cardiac surgery in patients with haemophilia B: a case report and review of the literature.
Krakow EF, Walker I, Lamy A, Anderson JA. Haemophilia. 2009 Jan;15(1):108-13. doi: 10.1111/j.1365-2516.2008.01918.x. Epub 2008 Oct 23. Review. PMID: 18976256

Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.
Mullah-Ali AM, Chan AK, Lillicrap D, Decker K, Seroski W, Moffat K, Walker I, Pai MK. Haemophilia. 2009 Nov;15(6):1258-61. doi: 10.1111/j.1365-2516.2009.02062.x. Epub 2009 Jun 26. PMID: 19563498

Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?
Iorio A, Marcucci M. Haemophilia. 2009 Jul;15(4):900-3. doi: 10.1111/j.1365-2516.2009.02031.x. Epub 2009 Apr 7. Review. PubMed PMID: 19473413.

Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.
Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M,Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM. Blood. 2009 Jul 23;114(4):779-84. doi: 10.1182/blood-2009-01-195313. Epub 2009 Apr 8. Review. PubMed PMID: 19357395.

Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C, Iorio A, Ferrante F, Pallotta A, Pignoloni P, Biondo F, Agnelli G, Mazzucconi MG. Haemophilia. 2009 May;15(3):779-87. doi: 10.1111/j.1365-2516.2009.01983.x. Epub 2009 Feb 27. PubMed PMID: 19298379.

Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase.
Iorio A, Basileo M, Marchesini E, Palazzesi GP, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Germani A, Rocchetti L, Silvani CM.Blood Transfus. 2008 Oct;6(4):211-9. PubMed PMID: 19112736; PubMed Central PMCID: PMC2626902.

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I; Association of Hemophilia Clinic Directors of Canada. Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8. PMID: 18194308

A case of non-resolving hemophilia B Leyden in a 42-year-old male (F9 promoter + 13 A>G).
James PD, Stakiw J, Leggo J, Walker I, Lillicrap D. J Thromb Haemost. 2008 May;6(5):885-6. doi: 10.1111/j.1538-7836.2008.02940.x. Epub 2008 Feb 25. PMID: 18315547

The good use of plasma. A critical analysis of five international guidelines.
Iorio A, Basileo M, Marchesini E, Materazzi M, Marchesi M, Esposito A, Palazzesi GP, Pellegrini L, Pasqua BL, Rocchetti L, Silvani CM. Blood Transfus. 2008 Jan;6(1):18-24. PubMed PMID: 18661920; PubMed Central PMCID: PMC2626858.

Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis.
Iorio A, Oliovecchio E, Morfini M, Mannucci PM. Haemophilia. 2008 May;14(3):444-53. doi: 10.1111/j.1365-2516.2008.01679.x. Epub 2008 Mar 18. Erratum in: Haemophilia. 2009 Mar;15(2):637. PubMed PMID: 18355268.

Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme.
Arnold DM, Webert KE, Carruthers J, Almonte T, Decker K, Seroski W, Reed J, Chan AK, Pai M, Walker I. Haemophilia. 2007 May;13(3):271-8. PMID: 17498076

Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study.
James PD, Notley C, Hegadorn C, Poon MC, Walker I, Rapson D, Lillicrap D; Association of Hemophilia Clinic Directors of Canada. J Thromb Haemost. 2007 Sep;5(9):1914-22. Epub 2007 Jun 26. PMID: 17596142

Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.
Webert KE, Arnold DM, Carruthers J, Molnar L, Almonte T, Decker K, Seroski W, Reed J, Chan AK, Pai M, Walker IR. Haemophilia. 2007 Sep;13(5):518-26. PMID: 17880438

Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up.
Arnold DM, Julian JA, Walker IR; Association of Hemophilia Clinic Directors of Canada. Blood. 2006 Jul 15;108(2):460-4. Epub 2006 Mar 21. PMID: 16551974

The UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing in haemophilia.
Perry DJ, Goodeve A, Hill M, Jennings I, Kitchen S, Walker I; UK NEQAS for Blood Coagulation. Thromb Haemost. 2006 Nov;96(5):597-601. PMID: 17080216

A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms.
Webert KE, Cook RJ, Couban S, Carruthers J, Heddle NM. Transfusion. 2006 Nov;46(11):1926-33. PubMed PMID: 17076848.

Can evidence harm? Certainly not hemophilia treatment and community.
Iorio A, Stobart K, Bolton-Maggs P. J Thromb Haemost. 2006 Mar;4(3):505-6. PubMed PMID: 16460430.

The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia.
Webert KE, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. Haematologica. 2006 Nov;91(11):1530-7. PubMed PMID: 17043016.

Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Stobart K, Iorio A, Wu JK. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003429. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003429. PubMed PMID: 15846666.

Handheld computers and paper diaries for documenting the use of factor concentrates used in haemophilia home therapy: a qualitative study.
Arnold E, Heddle N, Lane S, Sek J, Almonte T, Walker I. Haemophilia. 2005 May;11(3):216-26. PMID: 15876266

Handheld computers and paper diaries for documenting the use of factor concentrates used in haemophilia home therapy: a qualitative study.
Arnold E, Heddle N, Lane S, Sek J, Almonte T., Walker I. Haemophilia. 2005;11:216-26. PubMed PMID: 15876266.

Comparing hand-held computers and paper diaries for haemophilia home therapy: A randomized trial.
Walker I, Sigouin C, Sek J, Almonte T, Carruthers J, Chan A, Pai M, Heddle NM. Haemophilia. 2004;10(6):698-704. PubMed PMID: 15569164.

Comparing hand-held computers and paper diaries for haemophilia home therapy: a randomized trial.
Walker I, Sigouin C, Sek J, Almonte T, Carruthers J, Chan A, Pai M, Heddle N. Haemophilia. 2004 Nov;10(6):698-704. PMID: 15569164

A survey of factor prophylaxis in the Canadian haemophilia A population.
Blanchette P, Rivard G, Israels S, Robinson S, Ali K, Walker I, Stain AM, Blanchette V; Association of Hemophilia Clinic Directors of Canada and Canadian Association of Nurses in Hemophilia Care. Haemophilia. 2004 Nov;10(6):679-83. PMID: 15569161

Developing a tracking system for coagulation factor concentrates in southern Ontario.
Walker IR, Sek JT, Almonte TM, Carruthers JB, Chan AK, Pai MK, Thibault AA, Heddle NM. Transfusion. 2003 May;43(5):556-62. PMID: 12702174

Health status and health-related quality of life associated with von Willebrand disease.
Barr RD, Sek J, Horsman J, Furlong W, Saleh M, Pai M, Walker I. Am J Hematol. 2003 Jun;73(2):108-14. PMID: 12749012

Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada. Thromb Haemost. 2002 Feb;87(2):224-30. PMID: 11858481

Health status and health-related quality of life associated with hemophilia.
Barr RD, Saleh M, Furlong W, Horsman J, Sek J, Pai M, Walker I. Am J Hematol. 2002 Nov;71(3):152-60. PMID: 12410568

Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A.
Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, Sinclair GD, Pai M, Wu JW, Reddy S, Carter C, Growe G, Lillicrap D, Lam M, Blajchman MA. Thromb Haemost. 2000 Mar;83(3):387-91. PMID: 10744141

Loss of factor VIII activity during storage in PVC containers due to adsorption.
McLeod AG, Walker IR, Zheng S, Hayward CP. Haemophilia. 2000 Mar;6(2):89-92. PMID: 10781194

A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. Thromb Haemost. 1998 Apr;79(4):872-5. PMID: 9569207

Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada.
Walker IR, Julian JA. Haemophilia. 1998 Sep;4(5):714-20. PMID: 9873876

Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
Giles AR, Rivard GE, Teitel J, Walker I. Transfus Sci. 1998 Jun;19(2):139-48. PMID: 10187039

Hepatitis C infection in patients with hemophilia: results of a national survey. Canadian Hemophilia Clinic Directors Group.
Walker I, Pai M, Akabutu J, Ritchie B, Growe G, Poon MC, Card R, Ali K, Israels S, Teitel J, et al. Transfusion. 1995 Jul;35(7):548-51. PMID: 7631385

The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates.
Blanchette V, Walker I, Gill P, Adams M, Roberts R, Inwood M. Transfus Med Rev. 1994 Jul;8(3):210-7. Review. PMID: 8081082

Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group.
Walker I, Poon MC. Lancet. 1992 Jan 4;339(8784):61-2. PMID: 1345984

Survey of the Canadian hemophilia population.
Walker I. Can J Public Health. 1991 Mar-Apr;82(2):127-9. PMID: 2049704

Orthotopic liver transplantation in a patient with combined hemophilia A and B.
Delorme MA, Adams PC, Grant D, Ghent CN, Walker IR, Wall WJ. Am J Hematol. 1990 Feb;33(2):136-8. PMID: 2105634

The bleeding disorders: current concepts and management.
Walker IR. Can Fam Physician. 1988 Nov;34:2539-77. PMID: 21253126

Myositis ossificans in hemophilia.
Vas W, Cockshott WP, Martin RF, Pai MK, Walker I. Skeletal Radiol. 1981;7(1):27-31. PMID: 7336212